<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65590">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02251990</url>
  </required_header>
  <id_info>
    <org_study_id>5172-067</org_study_id>
    <nct_id>NCT02251990</nct_id>
  </id_info>
  <brief_title>Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)</brief_title>
  <official_title>A Phase III Randomized Multinational Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects With Chronic HCV GT 1, GT 4 and GT 6 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, parallel-group, placebo-controlled, multi-site, multinational,
      double-blind followed by open label period, Phase 3 trial of 100 mg of grazoprevir (MK-5172)
      in combination with 50 mg of elbasvir (MK-8742) (grazoprevir/elbasvir fixed-dose combination
      [FDC]) in treatment-naïve (TN) participants with chronic hepatitis C virus (HCV), genotype
      (GT) 1, 4 or 6 infection. The primary hypothesis is that the proportion of participants
      receiving grazoprevir/elbasvir FDC in the immediate treatment arm achieving SVR12 (Sustained
      Virologic Response 12 weeks after the end of all study therapy) will be superior to the
      reference rate of 73%.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants achieving SVR12</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing an adverse event (AE)</measure>
    <time_frame>Up to Week 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants discontinuing from study therapy due to AEs</measure>
    <time_frame>Up to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving SVR 4 weeks after ending all study treatment (SVR4)</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving SVR 24 weeks after ending all study treatment (SVR24)</measure>
    <time_frame>Week 36</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">489</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Grazoprevir/Elbasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants take a grazoprevir/elbasvir FDC tablet once daily (q.d.) by mouth for 12 weeks (active treatment period). Participants are then monitored for safety until Week 36.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants take a placebo tablet q.d. by mouth for 12 weeks (placebo treatment period). After a 4-week Follow-Up period, participants take grazoprevir/elbasvir FDC during a 12-week Active Treatment period (Week 16 to Week 28). Participants are then monitored for safety until Week 52.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grazoprevir/Elbasvir</intervention_name>
    <description>FDC tablet containing 100 mg of grazoprevir and 50 mg of elbasvir taken q.d. by mouth for 12 weeks.</description>
    <arm_group_label>Grazoprevir/Elbasvir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet matching grazoprevir/elbasvir FDC tablet taken q.d. by mouth for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has documented chronic HCV GT1, GT4, or GT6 (with no evidence of non-typeable or
             mixed genotype) infection

          -  Has or does not have cirrhosis of the liver

          -  Is abstinent or uses acceptable method(s) of contraception

        Exclusion Criteria:

          -  Has evidence of decompensated liver disease

          -  Is coinfected with hepatitis B virus or human immunodeficiency virus (HIV)

          -  Shows evidence of hepatocellular carcinoma (HCC) or is under evaluation for HCC

          -  Has a clinically-relevant drug or alcohol abuse within 12 months of screening

          -  Is pregnant or breast-feeding

          -  Has any condition or abnormality that might confound the results of the trial or pose
             an additional risk to the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Vietnam</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>September 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
